Boehringer Ingelheim

Found 2253 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

A Study in Healthy People to Compare Two Different Sifrol® Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole (from manufacturing site 1)
Drug: Pramipexole (from manufacturing site 2)

First Posted Date: 2024-06-13

Last Posted Date: 2024-08-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT06457204

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 3731579
Drug: Matching placebo to BI 3731579

First Posted Date: 2024-05-24

Last Posted Date: 2025-06-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT06429137

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Phase 3

Recruiting

Conditions: Heart Failure

Interventions: Drug: vicadrostat
Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2024-05-22

Last Posted Date: 2025-06-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6000

Registration Number: NCT06424288

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Diagnostic and Medical Clinic, Mobile, Alabama, United States
🇺🇸
Mobile Heart Specialists, PC, Mobile, Alabama, United States

and more 583 locations

A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 300202
Drug: esomeprazole

First Posted Date: 2024-05-17

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT06419660

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2024-05-16

Last Posted Date: 2024-07-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT06415045

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2024-05-10

Last Posted Date: 2024-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT06408870

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550 Formulation C2
Drug: BI 1015550 Formulation C1

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT06393127

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Phase 3

Withdrawn

Conditions: Myxofibrosarcoma (MFS)
Advanced Soft Tissue Sarcoma
Undifferentiated Pleomorphic Sarcoma (UPS)

Interventions: Drug: Ezabenlimab
Drug: Brigimadlin
Drug: Gemcitabine
Drug: Docetaxel

First Posted Date: 2024-04-17

Last Posted Date: 2024-07-17

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT06370871

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1569912
Drug: repaglinide
Drug: midazolam
Drug: bupropion

First Posted Date: 2024-04-16

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT06367153

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zongertinib

First Posted Date: 2024-04-11

Last Posted Date: 2025-05-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT06360081

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

AI-Powered Research

Premium Access

A Study in Healthy People to Compare Two Different Sifrol® Tablets

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers